Icosavax (Icosavax) Debt-to-Asset : 0.03 (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Icosavax Debt-to-Asset?

Icosavax's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $2.19 Mil. Icosavax's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $5.89 Mil. Icosavax's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2023 was $251.30 Mil. Icosavax's debt to asset for the quarter that ended in Sep. 2023 was 0.03.

Icosavax Debt-to-Asset Historical Data

The historical data trend for Icosavax's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Icosavax Debt-to-Asset Chart

Icosavax Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Debt-to-Asset

0.31

0.04

Icosavax Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-Asset	Get a 7-Day Free Trial											0.03	0.04	0.04	0.03	0.03

Competitive Comparison of Icosavax's Debt-to-Asset

For the Biotechnology subindustry, Icosavax's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Icosavax's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Icosavax's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Icosavax's Debt-to-Asset falls into.

Icosavax Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Icosavax's Debt-to-Asset for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(2.137	+	6.658)	/	238.677
	=	0.04

Icosavax's Debt-to-Asset for the quarter that ended in Sep. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(2.185	+	5.886)	/	251.296
	=	0.03

Icosavax (NAS:ICVX) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Icosavax Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Icosavax's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Icosavax (Icosavax) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Icosavax Inc (NAS:ICVX) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

1930 Boren Avenue, Suite 1000, Seattle, WA, USA, 98101

Website

https://www.icosavax.com

Icosavax Inc is a biopharmaceutical company. It is committed towards developing safe and effective vaccines against infectious diseases against infectious diseases, with an initial focus on life-threatening respiratory diseases.

Executives

Adam K. Simpson	director, officer: Chief Executive Officer	C/O ICOSAVAX, INC., 1616 EASTLAKE AVENUE E., SUITE 208, SEATTLE WA 98102
Niranjan Kanesa-thasan	officer: Chief Medical Officer	1616 EASTLAKE AVENUE E., SUITE 208, SEATTLE WA 98102
Cassia Cearley	officer: Chief Business Officer	1616 EASTLAKE AVENUE E., SUITE 208, SEATTLE WA 98102
Thomas Joseph Russo	officer: Chief Financial Officer	C/O ASSEMBLY BIOSCIENCES, INC., 11711 N MERIDIAN ST, SUITE 310, CARMEL IN 46032
Douglas Holtzman	officer: Chief Scientific Officer	1616 EASTLAKE AVENUE E., SUITE 208, SEATTLE WA 98102
Amin Khan	officer: EVP, Head of Research & Dev.	C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC, 200 BOSTON AVENUE, SUITE 3100, MEDFORD MA 02155
Ra Capital Nexus Fund, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Elizabeth Bekiroglu	officer: See Remarks	1616 EASTLAKE AVENUE E, SUITE 208, SEATTLE WA 98102-3793
Charles E Richardson	officer: See Remarks	1616 EASTLAKE AVENUE E., SUITE 208, SEATTLE WA 98102
Jim Wassil	director	C/O VAXCYTE, INC., 353 HATCH DRIVE, FOSTER CITY CA 94404
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
John W. Shiver	director	C/O ICOSAVAX, INC., 1616 EASTLAKE AVENUE E. SUITE 208, SEATTLE WA 98102
Anofi	10 percent owner	46 AVENUE DE LA GRANDE ARMEE, PARIS I0 75017
Nanodimension Iii, L.p.	10 percent owner	GOVERNORS SQUARE UNIT 3-213, 23 LIME TREE BAY AVE, P.O. BOX 526, WEST BAY, GRAND CAYMAN E9 KY1-1302
Adams Street Partners Llc	10 percent owner	ONE NORTH WACKER DRIVE, STE 2700, CHICAGO IL 60606-2807